Rivaroxaban — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Atrial Fibrillation (Stroke Prevention)

• Warfarin Sodium
• Amiodarone
• Apixaban
• Dabigatran
• Digoxin
• Metoprolol
• Warfarin

Also listed for Deep Vein Thrombosis

• Enoxaparin

Other medications in Heart & Cardiovascular

• Rosuvastatin
• Sacubitril-Valsartan
• Selexipag
• Sildenafil (PAH)
• Simvastatin
• Sotalol
• Tadalafil (PAH)
• Telmisartan

About Rivaroxaban

Rivaroxaban, a crucial medication for preventing dangerous blood clots, can often come with a hefty price tag. At TheDrugClub, we believe essential prescriptions shouldn't break the bank. ## What is Rivaroxaban and What Does It Treat? Rivaroxaban is an anticoagulant medication, commonly known as a blood thinner. Its primary role is to prevent the formation of harmful blood clots or to treat existing ones. Doctors prescribe rivaroxaban for several critical conditions, including:

• Preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AFib), an irregular heartbeat that can lead to clot formation. * Treating deep vein thrombosis (DVT), blood clots that form in a deep vein, usually in the legs. * Treating pulmonary embolism (PE), a serious condition where a blood clot travels to the lungs. * Preventing DVT and PE in patients undergoing certain surgeries, such as hip or knee replacement. * Reducing the risk of major cardiovascular events (like heart attack or stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). ## How Does Rivaroxaban Work? Rivaroxaban belongs to a class of drugs called direct oral anticoagulants (DOACs), specifically a direct Factor Xa inhibitor. In simpler terms, it targets a specific protein (Factor Xa) in the blood clotting cascade. By blocking this protein, rivaroxaban effectively slows down the process of blood clot formation. This action helps to prevent dangerous clots from forming in the first place or stops existing clots from growing larger, thereby reducing the risk of serious complications like stroke, heart attack, or further embolism. ## Typical Costs of Rivaroxaban

As a brand-name medication (Xarelto®), rivaroxaban can be quite expensive. Without insurance, or with a high-deductible plan, a month's supply can easily cost hundreds of dollars. Even with good insurance, co-pays can still be substantial, placing a significant financial burden on patients who need this medication long-term. The cost can vary depending on the dosage, pharmacy, and your specific insurance coverage, but it consistently ranks among the higher-priced prescription drugs. We understand that high medication costs shouldn't be a barrier to your health. That's right – zero dollars out of your pocket for your vital prescription. Beyond the incredible savings, TheDrugClub also offers free home delivery.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Rivaroxaban is approved for (FDA label)

XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.

Source: Read the full FDA label on DailyMed. Label effective date: September 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Rivaroxaban (FDA label)

WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A. Premature discontinuation of XARELTO increases the risk of thrombotic events Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3 , 2.4) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . B. Spinal/epidural hematoma Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the administration of XARELTO and neuraxial procedures is not known [see Warnings and Precautions (5.2 , 5.3) and Adverse Reactions (6.2) ]. Monitor patients frequently for signs and symptoms of neurological impairment.

Source: FDA prescribing information (DailyMed). Set ID: 10db92f9-2300-4a80-836b-673e1ae91610. SPL document ID: 5294926b-7812-41da-a0e8-56f492198450. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rivaroxaban (FDA label)

2.5 mg tablets: Round, light yellow, and film-coated with a triangle pointing down above a "2.5" marked on one side and "Xa" on the other side 10 mg tablets: Round, light red, biconvex and film-coated with a triangle pointing down above a "10" marked on one side and "Xa" on the other side 15 mg tablets: Round, red, biconvex, and film-coated with a triangle pointing down above a "15" marked on one side and "Xa" on the other side 20 mg tablets: Triangle-shaped, dark red, and film-coated with a triangle pointing down above a "20" marked on one side and "Xa" on the other side For oral suspension: white to off-white granules; once reconstituted, provide flavored white to off-white opaque liquid with a concentration of 1 mg/mL. Tablets: 2.5 mg, 10 mg, 15 mg, and 20 mg ( 3 ) For oral suspension: 1 mg/mL once reconstituted ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 10db92f9-2300-4a80-836b-673e1ae91610. SPL document ID: 5294926b-7812-41da-a0e8-56f492198450. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rivaroxaban (FDA label)

The following clinically significant adverse reactions are also discussed in other sections of the labeling: Increased Risk of Stroke After Discontinuation in Nonvalvular Atrial Fibrillation [see Boxed Warning and Warnings and Precautions (5.1) ] Bleeding Risk [see Warnings and Precautions (5.2 , 5.4 , 5.5 , 5.6 , 5.7) ] Spinal/Epidural Hematoma [see Boxed Warning and Warnings and Precautions (5.3) ] The most common adverse reaction (>5%) in adult patients was bleeding ( 6.1 ) The most common adverse reactions (>10%) in pediatric patients were bleeding, cough, vomiting, and gastroenteritis ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 10db92f9-2300-4a80-836b-673e1ae91610. SPL document ID: 5294926b-7812-41da-a0e8-56f492198450. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rivaroxaban (FDA label)

XARELTO is contraindicated in patients with: active pathological bleeding [see Warnings and Precautions (5.2) ] severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) [see Adverse Reactions (6.2) ] Active pathological bleeding ( 4 ) Severe hypersensitivity reaction to XARELTO ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 10db92f9-2300-4a80-836b-673e1ae91610. SPL document ID: 5294926b-7812-41da-a0e8-56f492198450. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rivaroxaban (FDA label)

Risk of bleeding: XARELTO can cause serious and fatal bleeding ( 5.2 ) Pregnancy-related hemorrhage: Use XARELTO with caution in pregnant women due to the potential for obstetric hemorrhage and/or emergent delivery ( 5.7 , 8.1 ) Prosthetic heart valves: XARELTO use not recommended ( 5.8 ) Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: XARELTO use not recommended ( 5.10 ) 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients.

Source: FDA prescribing information (DailyMed). Set ID: 10db92f9-2300-4a80-836b-673e1ae91610. SPL document ID: 5294926b-7812-41da-a0e8-56f492198450. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rivaroxaban (FDA label)

Avoid combined P-gp and strong CYP3A inhibitors and inducers ( 7.2 , 7.3 ) Anticoagulants: Avoid concomitant use ( 7.4 ) 7.1 General Inhibition and Induction Properties Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters, the latter also known as breast cancer resistance protein (BCRP). Combined P-gp and strong CYP3A inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding.

Source: FDA prescribing information (DailyMed). Set ID: 10db92f9-2300-4a80-836b-673e1ae91610. SPL document ID: 5294926b-7812-41da-a0e8-56f492198450. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.